PIPELINE

Small Molecule for Cataract and Presbyopia

Our approach to Cataract: Lanosterol

Lanosterol has the potential to be the first pharmacological therapy for cataract, a disease typically treated with surgical intervention.

Lanosterol has been identified as a key molecule in the reversal of lens protein aggregation. In preclinical studies, lanosterol was shown to significantly decrease protein aggregation. Lanosterol may be able to decrease cataracts by resolving aggregation of lens proteins, thereby reducing the need for surgery.